Can Glargine Reduce the Number of Lung Infections in Patients With Cystic Fibrosis–Related Diabetes?
- Adriana Franzese, MD1,
- Maria Immacolata Spagnuolo, MD, PHD1,
- Angela Sepe, MD1,
- Giuliana Valerio, MD, PHD2,
- Enza Mozzillo, MD1 and
- Valeria Raia, MD1
- 1Department of Pediatrics, Federico II University, Naples, Italy
- 2School of Movement Sciences (DiSIST), Parthenope University, Naples, Italy
- Address correspondence to Adriana Franzese, Department of Pediatrics, University Federico II, Naples, Italy, V S Pansini, 5, 80131 Naples, Italy. E-mail: franzese{at}unina.it
Incidence and prevalence of cystic fibrosis–related diabetes (CFRD) are rapidly increasing in recent years, according to the gradual increase in median survival age, which is now around 30 years (1). CFRD, with or without fasting hyperglycemia, may be chronic or intermittent, the latter in physically stressed patients. It is possible that the prediabetic state may have adverse effects on clinical status, nutrition, and lung function in patients with cystic fibrosis (2). As a matter of fact, impairment of lung function seems to appear up to 2–4 years before the clinical onset of diabetes. Insulin therapy was able to improve lung function in CFRD patients (3). Glargine is a recent long-acting insulin analog, which is …
